In addition, the protective effect of IL-10 against diabetic retinopathy supports further development of recombinant IL-10 analogs (such as Pegilodecakin) that delay disease progression by regulating inflammation of the retinal microenvironment. The gene discussed is IL10; the disease is diabetic retinopathy.